MorphoSys AG (MOR): Price and Financial Metrics


MorphoSys AG (MOR): $23.18

0.37 (+1.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MOR Stock Summary

  • The price/operating cash flow metric for MorphoSys AG is higher than 94.25% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of 1,860.84%, MorphoSys AG's debt growth rate surpasses 98.81% of about US stocks.
  • Revenue growth over the past 12 months for MorphoSys AG comes in at 356.69%, a number that bests 98.06% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to MOR, based on their financial statements, market capitalization, and price volatility, are OPGN, ASX, PDEX, KMDA, and MOSY.
  • Visit MOR's SEC page to see the company's official filings. To visit the company's web site, go to www.morphosys.com.

MOR Stock Price Chart Interactive Chart >

Price chart for MOR

MOR Price/Volume Stats

Current price $23.18 52-week high $35.73
Prev. close $22.81 52-week low $21.27
Day low $23.01 Volume 21,400
Day high $23.43 Avg. volume 59,326
50-day MA $24.11 Dividend yield N/A
200-day MA $28.31 Market Cap 3.05B

MorphoSys AG (MOR) Company Bio


MorphoSys AG engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. The company was founded in 1992 and is based in Planegg, Germany.

MOR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$23.18$0 -100%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for MorphoSys AG. To summarize, we found that MorphoSys AG ranked in the 0th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 100%. The most interesting components of our discounted cash flow analysis for MorphoSys AG ended up being:

  • 47% of the company's capital comes from equity, which is greater than only 15.99% of stocks in our cash flow based forecasting set.
  • As a business, MorphoSys AG experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than only 0% of stocks generating free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-100%
1%-100%
2%-100%
3%-100%
4%-100%
5%-100%

Want more companies with a valuation profile/forecast similar to that of MorphoSys AG? See AGHC, BMRN, EDAP, IONS, and IVC.


MOR Latest News Stream


Event/Time News Detail
Loading, please wait...

MOR Latest Social Stream


Loading social stream, please wait...

View Full MOR Social Stream

Latest MOR News From Around the Web

Below are the latest news stories about MorphoSys AG that investors may wish to consider to help them evaluate MOR as an investment opportunity.

Incyte (INCY), MorphoSys Initiate Dosing in Lymphoma Study

Incyte (INCY) and MorphoSys begin dosing in a study evaluating tafasitamab or placebo, in combination Revlimid and Rituxan, in patients with relapsed or refractory FL or marginal zone lymphoma.

Yahoo | April 20, 2021

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

First Patient Dosed in P3 inMIND Study Adding Tafasitamab + Lenalidomide to Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Yahoo | April 19, 2021

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / April 19, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL)."Despite improvements in treatment for patients with relapsed or refractory FL and MZL, there continues to be a significant medical need for additional therapies with improved outcomes," said Peter Langmuir, M.

Yahoo | April 19, 2021

Berenberg Bank Stick to Their Buy Rating for Morphosys Ag By Investing.com

Berenberg Bank Stick to Their Buy Rating for Morphosys Ag

Investing.com | March 17, 2021

MorphoSys AG (MOR) Q4 2020 Earnings Call Transcript

Now, I would like to turn the conference over to you, Dr. Julia Neugebauer. My name is Julia Neugebauer, Senior Director, Investor Relations at MorphoSys and it's my pleasure to welcome you to our fourth quarter and full year 2020 financial results conference call. Joining me on the call today are Jean-Paul Kress, Chief Executive Officer; Sung Lee, Chief Financial Officer; Roland Wandeler, Chief Operating Officer; and Malte Peters, Chief Research and Development Officer.

Yahoo | March 17, 2021

Read More 'MOR' Stories Here

MOR Price Returns

1-mo 6.48%
3-mo -21.13%
6-mo -11.63%
1-year -8.42%
3-year -7.83%
5-year N/A
YTD -18.21%
2020 -20.55%
2019 40.99%
2018 N/A
2017 N/A
2016 N/A

Continue Researching MOR

Here are a few links from around the web to help you further your research on MorphoSys AG's stock as an investment opportunity:

MorphoSys AG (MOR) Stock Price | Nasdaq
MorphoSys AG (MOR) Stock Quote, History and News - Yahoo Finance
MorphoSys AG (MOR) Stock Price and Basic Information | MarketWatch

Page generated in 1.1071 seconds.